New Medication for Osteoarthritis Knee Pain

Trial Objective

New Medication for Osteoarthritis Knee PainThe purpose of this trial is to determine if a new FDA-approved medication called  Hymovis™ is effective in reducing or eliminating pain in people with osteoarthritis in their knee. The medication will be injected into the participant’s knee using a pneumatic  external compression device called KneeTap™ guided by ultrasound. This study will determine how the knee joint fluid proteins react to this medication to help reduce cartilage loss and joint pain.


New enrollment for this trial is temporarily paused

Who Can Participate

Patients who have an x-ray confirming mild to moderate osteoarthritis in the knee. Participants must not have had a knee infection or knee surgery within 12 months or a cortisone injection within 3 months of starting the study. Participants must be able to walk six minutes without a cane or walker.

Age: 21-80    Gender: Any Gender

Estimated Time Commitment

5 visits over 12 months

Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Not Available

Trial Contact

For more information, contact:

Mary Gill

Mary Gill

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors


Principal Investigators


Request More Information

Due to concerns around COVID-19 and our focus on helping to meet this momentous challenge, we have temporarily paused enrollment for all trials requiring an in-person visit. Please feel free to request additional information about any of the trials we have posted and we will get back to you when enrollment resumes. For more resources and information on COVID-19 please visit our special coronavirus website at